Utilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure
Utilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure
Plasma proteomics is a powerful approach for discovering novel protein biomarkers of drug toxicity in various disease contexts. One such biomarker in cardiovascular disease is apolipoprotein M (ApoM), which plays a crucial role in lipid metabolism and transport and is known to have both anti-inflammatory and cardioprotective effects in the body. Studying ApoM using proteomics requires various approaches to understand its expression, modifications, interactions, and functions in the proteome.
Learn about:
- Association between ApoM and heart failure outcomes
- Effects of the chemotherapeutic drug doxorubicin on ApoM levels
- How ApoM heterozygosity affects the regulation of transcription factor EB
Ali Javaheri, MD
Assistant Professor, Medicine, Cardiovascular Division
Washington University School of Medicine in St. Louis
Ali Javaheri, MD, is Assistant Professor of Medicine and Investigator in the Center for Cardiovascular Research at Washington University in St. Louis, and broadly trained in multiple disciplines. His clinical expertise and training is in advanced heart failure, a syndrome with no cure that has a worse prognosis than many cancers (5 year 50% mortality). He has led and contributed to studies that have utilized proteomic strategies to uncover the importance of novel pathways in human heart failure. These studies have highlighted the important role of apolipoprotein M (ApoM). Reduced circulating ApoM is associated with poor prognosis in heart failure. Dr. Javaheri shows the ApoM-content of isolated high-density lipoprotein correlates strongly with its sphingosine-1-phosphate content; however, adjusting for sphingosine-1-phosphate levels only partially attenuated the association between ApoM and heart failure survival. Together with Dr. Mahmoud Nasr at Harvard Medical School, Dr. Javaheri recently filed a provisional patent for nanotherapies related to ApoM. His ongoing studies on ApoM suggest significant translational potential for this pathway in heart failure.
Utilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure
A presentation by Ali Javaheri, MD
More webinars
WebinarOpening the black box: Building and evaluating machine learning models for proteomics
Machine learning can be a powerful way to extract multivariate signals from high-dimensional proteomics data, but only when models are built and evaluated with rigor. In this on-demand webinar, explore a practical framework for developing predictive and explanatory models, with an emphasis on study design choices that help prevent data leakage, reduce overfitting, and improve reproducibility.
WebinarBeyond the trees: See the bigger biological picture with pathway enrichment analysis
Proteomic data holds enormous potential—but the biology is rarely contained in a single protein. When you’re handed a list of differentially abundant proteins, the next challenge is turning that list into a clear, testable story about mechanisms and processes.
WebinarFinding the signal: Identifying reproducible biomarkers in high-plex proteomics
In biomarker discovery, the challenge is rarely a lack of data. Rather, it is knowing how to separate meaningful biological signal from technical distraction. This webinar focuses on how to use univariate analysis as a practical and powerful entry point for biomarker discovery in high-plex proteomics studies.